Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes
Most patients relapsing with AML either fail to achieve second remission or have only brief
remissions. Patients more than 60 years of age or having histories of antecedent
hematological disorders, prior chemotherapy, or poor risk cytogenetics have generally only
short remissions and as a group have two year survivals of less than 10%. Equally patients
with myeloid blast crisis of CML often fail to achieve remission or have responses of only
brief duration. Laboratory studies have shown that AML leukemic blasts may be induced in
culture to differentiate into dendritic cells which in turn may be used activate autologous
lymphocytes to acquire leukemia specific cytotoxicity. This trial will assess the
feasibility of generation of dendritic cell activated lymphocytes, and toxicity and efficacy
of these activated cells given after reinduction chemotherapy. Before this study begins
some toxicity information will have been generated in a trial of similar cells given to CML
patients.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Richard Champlin, MD,BS
Principal Investigator
UT MD Anderson Cancer Center
United States: Food and Drug Administration
ID99-075
NCT00038870
January 2001
January 2003
Name | Location |
---|---|
UT MD Anderson Cancer Center | Houston, Texas 77030 |